Compare BOTJ & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | SERA |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.4M | 77.2M |
| IPO Year | 2015 | 2021 |
| Metric | BOTJ | SERA |
|---|---|---|
| Price | $20.95 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 86.5K |
| Earning Date | 04-29-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $4,003,000.00 | $81,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | 2.61 | ★ 5.19 |
| 52 Week Low | $13.03 | $1.37 |
| 52 Week High | $21.49 | $4.17 |
| Indicator | BOTJ | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 44.66 |
| Support Level | $20.00 | $1.80 |
| Resistance Level | $21.45 | $3.45 |
| Average True Range (ATR) | 0.39 | 0.21 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 73.54 | 48.15 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.